Turnstone Biologics Net Income

Turnstone Biologics (TSBX) currently reports a net income of $-47M as of June 2025. That compares with $-75M in the prior-year period — up 36.8% year over year. That is below the sector sector average of $98M. Use the charts on this page to explore Turnstone Biologics's net income history and peer comparisons.

Turnstone Biologics's net income increased from $-75M to $-47M — a 36.8% year-over-year increase (period ending June 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Turnstone Biologics's net income of $-47M is lower than the its sector sector average of $98M. That is roughly 148.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Turnstone Biologics reported $-47M in net income as of June 2025. That compares with $-75M in the prior-year period — up 36.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-47M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $98M. From there, open related valuation or income-statement pages for Turnstone Biologics, and consider following TSBX for alerts when major investors trade the stock.